The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness

Nov 4, 2024
1 min read

The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness, in Health Affairs

key takeaway: "We found that 15 scientific articles were collectively mentioned in 3666 documents supporting 5 common, inaccurate claims: opioids are effective for treatment of chronic, non-cancer pain; opioids are “rarely” addictive; “pseudo-addiction” is due to inadequate pain management; no opioid dose is too high; and screening tools can identify those at risk of developing addiction."

Recent Posts

See All

Mental Health of Youths Who Use Puberty Blockers

Mental Health of Youths Who Use Puberty Blockers, in JAMA Network Open key takeaway: "prescription of a puberty blocker was associated with decreased adjusted odds of mood disorder and suicidal though

Availability of Naloxone in Retail Pharmacies Following Introduction of Over-the-Counter Status

Availability of Naloxone in Retail Pharmacies Following Introduction of Over-the-Counter Status, in JAMA Network Open key takeaway: "61.4% of pharmacies reported same-day naloxone availability without

A Decade of Innovations and Insights from FDA’s “The Real Cost” Campaigns and Youth Prevention Efforts

A Decade of Innovations and Insights from FDA’s “The Real Cost” Campaigns and Youth Prevention Efforts, special issue of American Journal of Preventive Medicine key takeaway, from the conclusion artic

PROMOTING BEHAVIORAL HEALTH TEAM

A Committee of the Partnership for a Healthier Fairfax

The opioid industry's use of scientific evidence to advance claims about prescription opioid safety and effectiveness

Recent Posts

Comments